| Name | Title | Contact Details |
|---|
Surmodics partners with the world`s leading and emerging medical device, diagnostic and life sciences companies to develop and commercialize innovative products designed to improve lives by enabling the detection and treatment of disease. Following two recent acquisitions, the company is transforming its medical device business from being a provider of coating technologies, to offering whole-product solutions. Throughout its transformation, Surmodics` mission remains: to improve the detection and treatment of disease by using our technology to provide solutions to difficult medical device and diagnostic challenges
Hyperfine`s mission is to make MRI accessible to every patient, regardless of income or resources. Anytime. Anywhere. Hyperfine designed the Swoop™ Portable MR Imaging System to overcome patient transport and dedicated room requirements associated with fixed conventional MRI systems. The Swoop™ system plugs into a standard electrical outlet, uses an Apple iPad® for control, and produces images at a patient`s bedside within minutes, allowing care teams to gain clinical information quickly. Fierce Medtech recently recognized Hyperfine as a 2020 Fierce 15 company for its innovative and creative approach to developing solutions for healthcare providers and patients. Hyperfine is part of 4Catalyzer, a portfolio of health technology companies with facilities in Connecticut, New York City, Palo Alto, California, and Taiwan.
OXiGENE is a biopharmaceutical company developing new and improved therapeutics that have the potential to deliver significant medical benefits to patients with cancer and serious medical conditions. Our primary focus is developing first-in-class anti-vascular drugs referred to as vascular disrupting agents (VDAs). Our lead compound in clinical development is fosbretabulin. VDAs are a new and highly differentiated class of anti-vascular drug that target existing tumor vasculature, leading to extensive tumor cell death. VDAs target the tumor vasculature rather than the tumor cells and therefore have broad potential therapeutic utility in cancer. Because VDAs act differently than anti-angiogenic drugs or cytotoxic chemotherapy drugs, VDAs are potentially complementary with anti-angiogenic drugs and chemotherapeutic agents. OXiGENE has ongoing VDA drug development programs and is committed to advancing the science of VDAs and their potential as innovative therapies to address unmet medical needs.
Founded in 1983 and headquartered in Meriden, CT, Aplicare is a market leader in the formulation, production and packaging of topical antiseptic and personal care products for use in today's professional health care setting. Just recently, we expanded
FlagHouse is a Hasbrouck Heights, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.